Novonesis: The Probiotic Crack in the Merger Story

Nine-month growth held at 7% and the 2030 algorithm survived — but Human Health flipped from flat to decline, and the culprit is the one thing management spent three quarters saying it wasn't yet seeing.

NSIS-B.CO · Earnings Call · 2026-11-05

What held, and what broke

The headline was fine. Novonesis delivered 7% organic growth for the first nine months, sales of €3.37bn, an adjusted gross margin of 59.8% (up 90bps) and an adjusted EBITDA margin of 37.9%, with Q3 even better at 38.3%, up 120bps. Food & Beverages was the star — 12% for nine months, 14% in Q3 against a hard comparable — and management reaffirmed both the 7-8% full-year guide and the 6-9% through-2030 ambition. Ester Baiget's framing was relentlessly on-message: “The performance once again shows the strength of our diversified portfolio. We serve a broad range of industries, end markets and geographies with different underlying growth drivers.” — Ester Baiget, Chief Executive Officer · 2026-11-05 But a diversified portfolio is only as good as its weakest cylinder, and this quarter one of them misfired. Human Health was flat for nine months and fell 8% in Q3. The division that was the merger's premium growth story — the one cited in February as growing double digits "despite others struggling" — has become the drag. That is the change worth writing about.

From "consumer sentiment" warning to destocking reality

This was not a surprise arrival. It was a slow-moving train that management flagged and then watched arrive. In February, the caveat was forward-looking — potential US softness not yet seen. By May the language had hardened: “Short term, we are seeing some signs of a weakening U.S. consumer. There is, of course, the consumer sentiment out. We see fewer searches on online platforms for probiotics.” — Henrik Nielsen, Unclear, likely Senior Executive or Business Unit Leader · 2026-05-05 In August it was still framed as “an isolated case we see punctual also in North America dietary supplements” — Ester Baiget, CEO · 2026-08-20. This quarter the isolation broke. Nicola Tang asked precisely the right question — whether Q3's minus-8% was a run-rate or a one-off — and got the answer that matters: “we have seen a stronger de-stocking of our customers, which is affecting the sales for the end of the second quarter -- the third quarter and making that -- moving the year-end from slight growth to a slight decline.” — Ester Baiget, Chief Executive Officer · 2026-11-05 The consumer sentiment keyword that topped the company's own theme list back in Q2 has now propagated into the P&L; the inventory buildup vocabulary that once described a benign Animal one-off now describes a demand problem in Dietary Supplements. And the offline segment — capsules, traditional retail — is where Novonesis admits it has "relatively high exposure." Crucially, the recovery date is not next quarter. Management now expects US supplements back to growth only in the second half of 2027, while insisting the group's 6-9% is intact: “No change on the 6% to 9% for the company where we see Human Health growth, and we will see Human Health growing as a business next year also with Dietary Supplements in the second half.” — Ester Baiget, Chief Executive Officer · 2026-11-05 That is a twelve-month hole in the highest-quality part of the franchise, plugged by assumption.

The question management would not answer directly

Chetan Udeshi of JPMorgan asked the sharpest thing on the call: is this really consumer behaviour, or is it competitive pressure — unbranded, possibly Chinese-supplied probiotics colonising Amazon and the offline shelf?

I'm just curious how much of this probiotics pressure in the U.S. is just competitive pressure that Chinese players are now willing and able to supply into the U.S. probiotics market.
Chetan Udeshi, Analyst · 2026-11-05

Note that competitive pressure is a freshly elevated keyword in this quarter's theme set — not a phrase that loomed over the 2025 calls. The reply reframed rather than rebutted: “we're really in a very dynamic market where we see changes on the consumer preferences and also changes on the way that the market is evolving” — Ester Baiget, Chief Executive Officer · 2026-11-05, and later, on the size of the decline, “We're not immune to the decline of the market, which is also double digit.” — Ester Baiget, Chief Executive Officer · 2026-11-05 That last phrase does a lot of work: it concedes Novonesis is declining roughly in line with a shrinking channel, not outperforming it. For a company whose entire equity story is outgrowing every market it plays in, that is a meaningful tell. The offsetting evidence is real — HMO momentum, growth in the health-care-practitioner channel, double-digit probiotic growth into fresh dairy, and the Novo Nordisk GLP 1 synbiotic collaboration. The innovation pipeline in women's health, longevity and weight management is genuine. But those are promises against a realised miss.

Cash, CapEx, and the themes that quietly fell away

Two analysts — Soren Samsoe and Chetan Udeshi — pressed the same nerve from different angles: why isn't cash conversion tracking organic growth? Nine-month free cash flow before acquisitions fell €111.3m year-on-year to €557.1m (17% of sales), with CapEx at €340.9m (10.2%) and destined for the high end of 12-14% for the full year. Rainer Lehmann's defence was technical and, to be fair, coherent: “If you look at the core net working capital, we, of course, see the higher receivables on the back of a strong revenue. We also mentioned that we planned higher inventory levels. And we see right now over the 9 months, a decline in payables.” — Rainer Lehmann, Chief Financial Officer · 2026-11-05 Payables should reverse in Q4 with the CapEx skew. Still, the net working capital drag is now the second consecutive quarter in which the cash question has dominated Q&A — a pattern, not a blip. What is more telling is what has stopped being discussed. The Feed Enzyme Alliance — a top-5 theme as recently as Q1 2026, when it was the explicit bridge for margin accretion and revenue synergy — has effectively vanished from the narrative, subsumed into a generic "good 1 percentage point from sales synergies." Likewise High protein, once a flagship phrase for the dairy thesis, no longer leads the theme list. And the West Allis culture plant, the subject of repeated capacity-constraint questioning through 2026, came on ahead of schedule — and management confirmed it was never a binding constraint: “No, it has not been a revenue constraint. It was part of the plan.” — Ester Baiget, Chief Executive Officer · 2026-11-05 A deferred milestone that arrives early and turns out not to have mattered is its own small story.

The global read-across

One genuinely cross-sectional signal: tariff refund is a dominant global theme this quarter — it appears across industrial, consumer and healthcare reporters alike — and Novonesis is a participant, with US customer tariff refunds shaving H2 organic growth (up to ~40bps, per the prior call) while running through pricing. Sebastian Bray tried to gross up the pricing number to ~3%; Lehmann pushed back: “it is a net number that we, of course, show the close to 2% for the year-to-date... your estimation there regarding the tariffs is probably on a bit higher side. The impact is less.” — Rainer Lehmann, Chief Financial Officer · 2026-11-05 Minor, but it confirms the tariff refund distortion is now a standard feature of European specialty-chemical reporting, not a Novonesis quirk.

Bottom line

The company is not broken. Food & Beverages compounding at mid-teens, energy double-digit, 38%+ margins, leverage heading to 1.8x and a maiden €75m buyback underway. But the narrative has shifted from "is this growth too good to be true?" (the question asked in August) to "which cylinder is misfiring and for how long?" Management's answer is one division, one geography, one channel, and twenty-four months. The market's answer will depend on whether the offline-supplement decline looks like a cycle or a share problem — and on that, the CEO chose vocabulary over arithmetic.